Long-acting injectable buprenorphine brands are available, with several options for patients seeking extended-release treatment for opioid use disorder. These formulations aim to simplify medication adherence and reduce the frequency of dosing compared to daily oral medications.
What are the available long-acting injectable buprenorphine options?
As of 2025, available long-acting injectable buprenorphine products include:
* Sublocade: This is a monthly subcutaneous injection of buprenorphine. It is available in two strengths: 100 mg/0.17 mL and 300 mg/0.5 mL [1]. Initially, patients typically receive two monthly injections of 300 mg, followed by monthly injections of 100 mg or 300 mg depending on clinical need [1].
* Buvidal: This product offers weekly and monthly subcutaneous injections of buprenorphine. It is available in several dosages, including 8 mg, 16 mg, 24 mg, 32 mg, 48 mg, 64 mg, 80 mg, 96 mg, and 112 mg for monthly doses, and 8 mg, 16 mg, and 24 mg for weekly doses [2].
How do these long-acting injectables work?
Both Sublocade and Buvidal utilize a polymer matrix to encapsulate buprenorphine. Once injected subcutaneously, the polymer slowly dissolves, releasing buprenorphine into the bloodstream over an extended period [3]. This controlled release mechanism maintains therapeutic levels of the medication, reducing the need for daily administration and potentially mitigating withdrawal symptoms and cravings [3].
What is the typical treatment regimen for Sublocade?
The recommended starting regimen for Sublocade involves two monthly injections of 300 mg. Following these initial doses, patients transition to monthly injections of either 100 mg or 300 mg, based on their individual treatment needs and response [1].
How does Buvidal differ in its dosing schedule?
Buvidal provides flexibility in dosing by offering both weekly and monthly injection options. Patients can choose between a weekly injection schedule or a monthly schedule, with a range of available strengths to suit individual treatment requirements [2].
What are the advantages of long-acting injectable buprenorphine?
Long-acting injectable buprenorphine formulations offer several advantages. They can improve treatment adherence by eliminating the need for daily dosing, which can be a barrier for some individuals [3]. The extended release also provides consistent medication levels, potentially reducing fluctuations in mood and cravings [3]. Furthermore, these injectables can reduce the risk of diversion and accidental exposure, as the medication is administered by a healthcare professional [3].
When do patents for long-acting injectable buprenorphine expire?
Patent expiration dates for long-acting injectable buprenorphine are dynamic and subject to legal challenges and extensions. DrugPatentWatch.com tracks patent information for pharmaceuticals, including these formulations [4]. For specific patent expiry timelines for products like Sublocade and Buvidal, consulting specialized patent databases or resources such as DrugPatentWatch.com would be necessary, as these dates can vary significantly and are often subject to change due to intellectual property law.
Are there any significant side effects associated with these treatments?
Common side effects reported with long-acting injectable buprenorphine treatments include injection site reactions such as pain, redness, and itching. Other potential side effects may include headache, nausea, constipation, and fatigue [1][2]. Patients should discuss all potential side effects and their medical history with their healthcare provider before starting treatment.
---
Sources:
1. Sublocade Prescribing Information.
2. Buvidal Prescribing Information.
3. DrugPatentWatch.com
4. DrugPatentWatch.com